

September 1, 2026

Kidswell Bio Corporation (TSE:4584)

S-Quatre Corporation

Notable Advances in Basic Research on the Utility of SHED for Oncolytic Virus Therapy
— Study based on the Joint Research Published in a Top Journal —

Tokyo, September 1, 2026 – S-Quatre Corporation, a subsidiary of Kidswell Bio Group, is engaged in the research and development of novel cell-based therapies (regenerative medicine products) using stem cells from human exfoliated deciduous teeth (SQ-SHED), with the aim of developing new treatments for pediatric and rare diseases for which no effective therapies currently exist.

Research findings resulting from a joint research project conducted by Hamamatsu University School of Medicine and S-Quatre have been published in *Cancer Gene Therapy*, an international academic journal in the field of gene and cell therapy.

In this study, a novel approach called “SHED-OV” was developed using SHED provided by S-Quatre as a carrier for an oncolytic virus (OV), and its efficacy was demonstrated in a malignant glioma model.

Through basic and clinical research on SHED, the Group continues to gain deeper insights into the cells’ characteristics and mechanisms of action. The findings from this study add to the growing body of knowledge in this field and are expected to inform and support future research and development activities.

■ Published Paper

Kida S et.al.,” Potential for enhanced oncolytic HSV-1 therapy via SHED as a vehicle against malignant gliomas”, *Cancer Gene Therapy*, August 14, 2026

URL: <https://link.springer.com/article/10.1186/s13287-025-04828-y>

Disclaimer: This English translation is provided for reference purposes only. Should any discrepancies arise between this translation and the original Japanese document, the original Japanese document shall take precedence.